Replies to post #83011 on Biotech Values

[exwannabe]

Re: SNY’s Otamixaban Is Unimpressive ..

"SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage."

OK, am I brain dead or anal on questioning what this says?